Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5DO9L
|
|||
| Drug Name |
Brolucizumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Wet age-related macular degeneration [ICD-11: 9B78.3Z; ICD-10: H35.31] | Approved | [1] | |
| Diabetic macular edema [ICD-11: 9B71.02] | Phase 3 | [2] | ||
| Company |
Alcon
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | ClinicalTrials.gov (NCT04058067) To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). U.S. National Institutes of Health. | |||
| REF 3 | Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.